Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019025588) METHODS OF TREATING BEHAVIOR ALTERATIONS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

1. A KDM1A inhibitor for use in the treatment of a behavior alteration.

2. A pharmaceutical composition for use in the treatment of a behavior alteration, wherein the pharmaceutical composition comprises a KDM1A inhibitor and one or more pharmaceutically acceptable excipients or carriers.

3. The compound for use according to claim 1 or the pharmaceutical composition for use according to claim 2, wherein the behavior alteration is a social behavior alteration.

4. The compound for use according to claim 1 or 3 or the pharmaceutical composition for use according to claim 2 or 3, wherein the behavior alteration is social withdrawal.

5. The compound for use according to claim 1 or 3 or the pharmaceutical composition for use according to claim 2 or 3, wherein the behavior alteration is aggressiveness.

6. The compound for use according to any one of claims 1 or 3 to 5 or the pharmaceutical composition for use according to any one of claims 2 to 5, wherein the patient to be treated is a human.

7. The compound for use according to any one of claims 1 or 3 to 6 or the pharmaceutical composition for use according to any one of claims 2 to 6, wherein the KDM1A inhibitor is 5-(({(1R,2S)-2-(4- (benzyloxy)phenyl)cyclopropyl)amino)methyl)-1 ,3,4-oxadiazol-2-amine, or a pharmaceutically acceptable salt or solvate thereof.

8. The compound for use according to any one of claims 1 or 3 to 7 or the pharmaceutical composition for use according to any one of claims 2 to 7, wherein the KDM1A inhibitor or the pharmaceutical composition is administered orally.

9. A method for treating a behavior alteration in a patient, comprising administering to the patient a therapeutically effective amount of a KDM1A inhibitor.

10. The method according to claim 9, wherein the behavior alteration is a social behavior alteration.

11. The method according to claim 9 or 10, wherein the behavior alteration is social withdrawal.

12. The method according to claim 9 or 10, wherein the behavior alteration is aggressiveness.

13. The method according to any one of claims 9 to 12, wherein the patient to be treated is a human.

14. The method according to any one of claims 9 to 13, wherein the KDM1A inhibitor is 5-((((1 R,2S)-2-(4- (benzyloxy)phenyl)cyclopropyl)amino)methyl)-1 ,3,4-oxadiazoi-2-amine, or a pharmaceutically acceptable salt or solvate thereof.

15. The method according to any one of claims 9 to 14, wherein the method comprises orally administering the KDM1A inhibitor.

16. Use of a KDM1A inhibitor for the manufacture of a medicament for the treatment of a behavior alteration.

17. The use according to claim 16, wherein the behavior alteration is a social behavior alteration.

18. The use according to claim 16 or 17, wherein the behavior alteration is social withdrawal.

19. The use according to claim 16 or 17, wherein the behavior alteration is aggressiveness.

20. The use according to any one of claims 16 to 19, wherein the patient to be treated is a human.

21. The use according to any one of claims 16 to 20, wherein the D 1A inhibitor is 5-((((1R,2S)-2-(4- (benzyioxy)phenyl)cyclopropyl)amino)methyi)-1,3,4-oxadiazol-2-amine, or a pharmaceutically acceptable salt or solvate thereof.

22. The use according to any one of claims 16 to 21, wherein the medicament is for oral administration.

23. Use of a KDM1 A inhibitor for the treatment of a behavior alteration.

24. The use according to claim 23, wherein the behavior alteration is a social behavior alteration.

25. The use according to claim 23 or 24, wherein the behavior alteration is social withdrawal.

26. The use according to claim 23 or 24, wherein the behavior alteration is aggressiveness.

27. The use according to any one of claims 23 to 26, wherein the patient to be treated is a human.

28. The use according to any one of claims 23 to 27, wherein the KDM1A inhibitor is 5-((((1R,2S)-2-(4- (benzyloxy)phenyl)cyclopropyl)amino)methyi)-1 ,3,4-oxadiazol-2-amine, or a pharmaceutically acceptable salt or solvate thereof.

29. The use according to any one of claims 23 to 28, wherein the KDM1A inhibitor is administered orally.